VTX3232, a CNS-penetrant oral NLRP3 inhibitor by Ventyx Biosciences, showed safety and IL-1β inhibition in a Phase 1 trial and is now in a Phase 2a trial for early PD (NCT06556173)[44]. The gene discussed is NLRP3; the disease is Parkinson disease.